Ph.D., CEO, Co-Founder, OneThree Biotech
Biography
Prior to founding OneThree, Dr. Madhukar obtained his PhD from Weill Cornell, where his research focused on designing new machine learning architectures for drug discovery. During this time he authored 40+ scientific publications in the fields of machine learning, drug discovery, and precision medicine. His work has led to the development of new AI prediction methods, the discovery of a novel class of cancer therapeutics, and the start of new clinical trials. Dr. Madhukar is an awardee of the PhRMA informatics fellowship, was named one of Forbes “30 under 30” in Healthcare, and was named as one of the top 100 AI Leaders in Drug Discovery and Advanced Healthcare by Deep Knowledge Analytics.
Talk
AI and Data Sciences Showcase:
OneThree Biotech
OneThree Biotech has developed an AI platform to identify new therapeutic opportunities (e.g. novel cancer targets, genetic interactions, or disease mechanisms) that were missed by current techniques. From this they're building a pipeline of first-in-class cancer therapeutics
The ATLANTIS Platform for Novel Target Discovery
How the ATLANTIS platform accelerates the discovery and derisking of novel disease targets
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S1 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S1 - January 26 11.30 A.M.-1.15 P.M.,Showcase Track S1 - January 27 11.00 A.M.-1.15 P.M.
The PMWC 2023 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
